{"nctId":"NCT01061151","briefTitle":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","startDateStruct":{"date":"2011-03-01","type":"ACTUAL"},"conditions":["HIV Infections"],"count":3747,"armGroups":[{"label":"Antepartum Arm A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zidovudine (ZDV)","Drug: Nevirapine (NVP): Antepartum Mothers","Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail","Drug: Nevirapine (NVP): Infant short-course"]},{"label":"Antepartum Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: Lamivudine-Zidovudine (3TC-ZDV)","Drug: Lopinavir-ritonavir (LPV-RTV)","Drug: Nevirapine (NVP): Infant short-course"]},{"label":"Antepartum Arm C","type":"EXPERIMENTAL","interventionNames":["Drug: Lopinavir-ritonavir (LPV-RTV)","Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])","Drug: Nevirapine (NVP): Infant short-course"]},{"label":"Late Presenters","type":"OTHER","interventionNames":["Other: No Intervention"]},{"label":"Postpartum Arm A (Maternal Prophylaxis)","type":"EXPERIMENTAL","interventionNames":["Drug: Lopinavir-ritonavir (LPV-RTV)","Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])","Drug: Nevirapine (NVP): Infant short-course"]},{"label":"Postpartum Arm B (Infant Prophylaxis)","type":"EXPERIMENTAL","interventionNames":["Drug: Nevirapine (NVP): Infant extended"]},{"label":"Maternal Health Arm A (Continue triple ARVs)","type":"EXPERIMENTAL","interventionNames":["Other: Continue triple ARVs"]},{"label":"Maternal Health Arm B (Discontinue triple ARVs)","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Discontinue triple ARVs"]}],"interventions":[{"name":"Zidovudine (ZDV)","otherNames":[]},{"name":"Nevirapine (NVP): Antepartum Mothers","otherNames":[]},{"name":"Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail","otherNames":[]},{"name":"Lamivudine-Zidovudine (3TC-ZDV)","otherNames":[]},{"name":"Lopinavir-ritonavir (LPV-RTV)","otherNames":[]},{"name":"Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])","otherNames":[]},{"name":"Nevirapine (NVP): Infant short-course","otherNames":[]},{"name":"Nevirapine (NVP): Infant extended","otherNames":[]},{"name":"No Intervention","otherNames":[]},{"name":"Discontinue triple ARVs","otherNames":[]},{"name":"Continue triple ARVs","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Antepartum Component Inclusion Criteria:\n\n* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information on this criterion can be found in the protocol.\n* Currently pregnant and greater than or equal to 14 weeks gestation based on clinical or other obstetrical measurements\n* CD4 count greater than or equal to 350 cells/mm\\^3, or greater than or equal to the country-specific threshold for initiation of treatment (if that threshold is greater than 350 cells/mm\\^3), on a specimen obtained within 30 days prior to study entry\n* Results of HBV screening (HBsAg testing) available from specimen obtained within 30 days prior to study entry\n* The following laboratory values from a specimen obtained within 30 days prior to study entry:\n\n  1. Hemoglobin greater than or equal to 7.5 g/dL\n  2. White blood cell count (WBC) greater than or equal to 1,500 cells/mm\\^3\n  3. Absolute neutrophil count (ANC) greater than or equal to 750 cells/mm\\^3\n  4. Platelets greater than or equal to 50,000 cells/mm\\^3\n  5. Alanine aminotransferase (ALT) less than or equal to 2.5 times the upper limit of normal (ULN)\n  6. Estimated creatinine clearance of greater than or equal to 60 mL/min using the Cockroft-Gault equation for women\n* Plans to deliver in the study-affiliated clinic or hospital\n* Has no plans to move outside of the study site area during the 24 months following delivery\n* Age of legal majority for the respective country and willing and able to provide written informed consent\n\nAntepartum Component Exclusion Criteria:\n\n* Participation in PROMISE for a prior pregnancy\n* Ingestion of any antiretroviral (ARV) regimen with three or more drugs (regardless of duration) or more than 30 days of a single or dual ARV regimen during current pregnancy, according to self report or available medical records\n* Requires triple ARV therapy (HAART) for own health based on local standard guidelines\n* World Health Organization (WHO) stage 4 disease\n* Prior receipt of HAART for maternal treatment indications (e.g., CD4 less than 350 cells/mm\\^3 or clinical indications); however, could have received ARVs for the sole purpose of prevention of mother-to-child transmission (PMTCT) in previous pregnancies (prior PMTCT regimens could have included a triple ARV regimen, ZDV, 3TC-ZDV, and/or sdNVP for PMTCT, as well as use of a short dual nucleoside reverse transcriptase inhibitor \\[NRTI\\] \"tail\" to reduce risk of NVP resistance.)\n* In labor - at onset or beyond (may be eligible for the Late Presenter registration)\n* Clinically significant illness or condition requiring systemic treatment and/or hospitalization within 30 days prior to study entry\n* Current or history of tuberculosis (TB) disease (positive PPD without TB disease is not exclusionary)\n* Use of prohibited medications within 14 days prior to study entry (refer to the protocol for a list of prohibited medications)\n* Fetus detected to have serious congenital malformation (ultrasound not required to rule out this condition)\n* Current documented conduction heart defect (specialized assessments to rule out this condition are not required; a heart murmur alone and/or type 1 second-degree atrioventricular block \\[also known as Mobitz I or Wenckebach\\] is not considered exclusionary)\n* Known to meet the local standard criteria for treatment of HBV (Note: HBV DNA testing or other specialized assessments are not expected to be performed as part of this study. A woman would be excluded only if this information is documented from other sources and she meets the local standard criteria for HBV treatment based on those assessments.)\n* Social or other circumstances that would hinder long-term follow-up, in the opinion of the site investigator\n* Currently incarcerated\n\nLate Presenter Inclusion Criteria:\n\n* Age of legal majority for the respective country\n* HIV-1 infection, defined as documented positive results from tests performed on one sample at any time prior to Late Presenter Registration\n* In labor (from onset/early labor or beyond) or within 5 days after delivery (with day of delivery considered day 0)\n* Has provided written informed consent\n* Has no plans to move outside of the study site area during the 24 months following delivery\n* If delivered, infant alive and healthy (In the case of a multiple birth, a mother-infant pair will be included in the Late Presenter registration only if both/all infants and the mother meet the eligibility criteria. If only one infant of a multiple birth is alive, the M-I pair may be registered if the infant and the mother otherwise meet all of the eligibility criteria.)\n\nLate Presenter Exclusion Criteria:\n\n* Participation in PROMISE in prior pregnancy\n* Ingestion of any antiretroviral regimen during current pregnancy (including for solely for PMTCT), according to self report and available medical records (Note: Use of ARVs provided as standard of care for PMTCT during labor/delivery or postpartum prior to Late Presenter registration is not exclusionary.)\n* If known: CD4 count \\< 350 cells/mm3 or below the country-specific threshold for initiation of treatment, if that threshold is \\> 350 cells/mm3, on specimen obtained within 30 days prior to study entry (result not required prior to registration)\n* Requires triple ARV therapy (HAART) for own health according to local standard guidelines\n* WHO Stage 4 disease\n* Prior receipt of HAART for maternal treatment indications (e.g., CD4 \\< 350 cells/mm3 or clinical indications); however, could have received ARVs for the sole purpose of PMTCT in previous pregnancies. (Prior PMTCT regimens could have included a triple ARV regimen, ZDV, 3TCZDV and/or sdNVP for PMTCT, as well as use of a short dual NRTI \"tail\" to reduce risk of NVP resistance.)\n* Current or history of TB disease (positive PPD without TB disease is not exclusionary)\n* Known positive infant HIV nucleic acid test (NAT) result (result not required prior to registration)\n* Fetal demise or early neonatal death (prior to enrollment/registration)\n* Fetus detected with serious congenital malformation (ultrasound not required to rule out this condition)\n* Life threatening infant illness or birth condition incompatible with life\n* If delivered, infant birth weight \\< 2.0 kg\n* Social or other circumstances which would hinder long-term follow-up, in the opinion of the site investigator\n* Current documented conduction heart defect (specialized assessments to rule out this condition are not required; a heart murmur alone and/or type 1 second-degree atrioventricular block (also known as Mobitz I or Wenckebach) is not considered exclusionary)\n\nPostpartum Component Inclusion Criteria:\n\n* Participation in the Antepartum Component or registered as a Late Presenter\n* Provided written informed consent\n* Has no plans to move outside of the study site area during the 24 months following delivery\n* Maternal CD4 count greater than or equal to 350 cells/mm\\^3, or greater than or equal to the country-specific threshold for initiation of treatment (if that threshold is greater than 350 cells/mm\\^3), from a specimen obtained within 30 days prior to study entry. More information on this criterion can be found in the protocol.\n* The following maternal laboratory values within 30 days prior to entry:\n\n  1. Hemoglobin greater than or equal to 7.0 g/dL\n  2. WBC greater than or equal to 1,500 cells/mm\\^3\n  3. ANC greater than or equal to 750 cells/mm\\^3\n  4. Platelets greater than or equal to 50,000 cells/mm\\^3\n  5. ALT less than or equal to 2.5 times the upper limit of normal (ULN)\n  6. Estimated creatinine clearance of greater than or equal to 60 mL/min using the Cockroft-Gault equation for women\n* Infant alive, healthy, less than or equal to 14 days of age, and uninfected (negative HIV NAT result on specimen drawn prior to study entry)\n* The following infant lab values on specimen obtained prior to study entry (within 14 days of birth):\n\n  1. Hemoglobin greater than or equal to 10 g/dL\n  2. WBC greater than or equal to 1,500 cells/mm\\^3\n  3. ANC greater than or equal to 750 cells/mm\\^3\n  4. Platelets greater than or equal to 50,000 cells/mm\\^3\n  5. ALT less than or equal to 2.5 times the ULN\n* For Registered Late Presenters: Confirmed maternal HIV-1 infection, defined as documented positive results from two samples collected at different time points at any time prior to entry. More information on this criterion can be found in the protocol.\n\nPostpartum Component Exclusion Criteria:\n\n* Positive infant HIV NAT result on specimen drawn prior to entry or no infant HIV NAT result on specimen drawn prior to entry\n* Life-threatening infant illness or birth condition incompatible with life\n* Infant birth weight less than 2.0 kg\n* Social or other circumstances that would hinder long-term follow-up, as judged by the site investigator\n* Current or history of TB disease (positive PPD without TB disease is not exclusionary)\n* Current documented conduction heart defect (specialized assessments to rule out this condition are not required; a heart murmur alone and/or type 1 second-degree atrioventricular block \\[also known as Mobitz I or Wenckebach\\] is not considered exclusionary)\n* Requires triple ARV therapy (HAART) for own health\n\nMaternal Health Component Inclusion Criteria:\n\n* Randomly assigned to triple ARV prophylaxis as part of the Postpartum Component and has continued triple ARV prophylaxis until the current randomization without treatment interruption (defined as more than 14 consecutive days of missed dosing) within the previous 30 days; OR randomly assigned to triple ARV prophylaxis in the Antepartum Component but ineligible for the Postpartum Component and has continued triple ARV prophylaxis until the current randomization without treatment interruption (defined as more than 7 consecutive days of missed dosing) within the previous 30 days\n* Within two weeks after complete breastfeeding cessation is achieved (defined as completely stopping all exposure to breast milk for greater than or equal to 28 days); i.e., within 29 to 42 days of last breast milk exposure, or reached 18 months postpartum (whichever comes first). Women who reach 18 months postpartum while still breastfeeding will be eligible for entry within 2 weeks before and 4 weeks after the Week 74 visit (Week 72-78); OR if the woman was randomized to triple ARV prophylaxis in the Postpartum Component and her infant is infected and still breastfeeding, she will be eligible for the Maternal Health Component within 42 days of specimen collection for the confirmatory infant HIV NAT; OR if the woman was randomized to triple ARV prophylaxis in the Antepartum Component but mother-infant pair was ineligible for the Postpartum Component she will be eligible for the Maternal Health Component beginning at the Week 1 visit (6-14 days postpartum) through 28 days after delivery; these women should be randomized as soon as possible, ideally within 6-14 days after delivery; OR if the woman was randomized to triple ARV prophylaxis in the Postpartum Component and breastfeeding risk for MTCT ceases for other reasons (e.g., infant death or permanent removal from home through legal services or adoption) within 28 days of event. More information on this criterion can be found in the protocol.\n* Provided written informed consent\n* CD4 cell count greater than or equal to 350 cells/mm\\^3, or greater than or equal to the country-specific threshold for initiation of treatment (if that threshold is greater than 350 cells/mm\\^3), on a specimen obtained within 30 days prior to study entry\n* The following laboratory values on a specimen obtained within 30 days prior to study entry:\n\n  1. ANC greater than or equal to 750 cells/mm\\^3\n  2. Hemoglobin greater than or equal to 7.0 gm/dL\n  3. Platelet count greater than or equal to 50,000 cells/mm\\^3\n  4. ALT (SGPT) less than or equal to 2.5 times the ULN\n  5. Estimated creatinine clearance of greater than or equal to 60 mL/min using the Cockroft-Gault equation for women\n* Intend to remain in current geographical area of residence for the duration of study\n\nMaternal Health Component Exclusion Criteria:\n\n* WHO Stage 4 disease\n* Clinically significant illness or condition requiring systemic treatment and/or hospitalization within 30 days prior to study entry\n* Current or history of TB disease (positive PPD without TB disease is not exclusionary)\n* Use of prohibited medications within 14 days prior to study entry\n* Social or other circumstances that would hinder long term follow-up as judged by the site investigator\n* Current documented conduction heart defect (specialized assessments to rule out this condition are not required; a heart murmur alone and/or type 1 second-degree atrioventricular block \\[also known as Mobitz I or Wenckebach\\] is not considered exclusionary)\n* Requires a triple ARV regimen for own health","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Antepartum Component: Number of Confirmed Infant HIV Infections","description":"Defined as HIV nucleic acid test (NAT) positivity of the specimen drawn at either the birth (Day 0-5) or Week 1 (Day 6-14) visit, confirmed by HIV NAT positivity of a second specimen collected at a different time point","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events","description":"These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"261","spread":null},{"groupId":"OG001","value":"318","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"PRIMARY","title":"Antepartum Component: Number of Mothers With Obstetrical Complications","description":"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as \"Pregnancy, puerperium and perinatal conditions\", except if the condition was the death of the fetus: \"Abortions not specified as induced or spontaneous\", \"Abortions spontaneous\", or \"Stillbirth and foetal death.\"","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)","description":"Composite outcome","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"563","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"111","spread":null}]}]}]},{"type":"PRIMARY","title":"Postpartum Component: Incidence of Confirmed Infant HIV Infection","description":"Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit (i.e., any visit after the Week 1 \\[Day 6-14\\] visit), confirmed by HIV NAT positivity of a second specimen drawn at a different time point. Analyses were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":null},{"groupId":"OG001","value":"0.55","spread":null}]}]}]},{"type":"PRIMARY","title":"Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events","description":"These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"14.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Maternal Health Component: Incidence of Progression to AIDS-defining Illness or Death","description":"AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses in Appendix IV of the protocol. These events were reviewed and confirmed by an Endpoint review group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Antepartum Component: Number of Infant HIV Infections","description":"Detected by HIV NAT positivity","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)","description":"For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.959","spread":null},{"groupId":"OG001","value":"0.967","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.951","spread":null},{"groupId":"OG001","value":"0.982","spread":null},{"groupId":"OG002","value":"0.942","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.937","spread":null},{"groupId":"OG001","value":"0.947","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.936","spread":null},{"groupId":"OG001","value":"0.940","spread":null},{"groupId":"OG002","value":"0.921","spread":null}]}]}]},{"type":"SECONDARY","title":"Antepartum Component: Maternal HIV RNA Less Than 400 Copies/mL at Delivery","description":"Analysis used the principle of intent to treat.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"415","spread":null},{"groupId":"OG001","value":"1092","spread":null}]},{"measurements":[{"groupId":"OG000","value":"929","spread":null},{"groupId":"OG001","value":"275","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"259","spread":null},{"groupId":"OG002","value":"225","spread":null}]},{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Postpartum Component: Proportion of Mother-Infant Pairs With no Death or HIV Diagnosis Through 24 Months Post-delivery","description":"Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit, confirmed by HIV NAT positivity of a second specimen drawn at a different time point, or infant death. Analyses (Kaplan-Meier probabilities) were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.971","spread":null},{"groupId":"OG001","value":"0.977","spread":null}]}]}]},{"type":"SECONDARY","title":"Postpartum Component: Proportion of Infants Alive Through 12 and 24 Months Post-delivery","description":"Analyses (Kaplan-Meier probabilities) conducted for all individual infants (rather than M-I pair)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.988","spread":null},{"groupId":"OG001","value":"0.989","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.978","spread":null},{"groupId":"OG001","value":"0.987","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence of Death","description":"Number of women who died during the maternal health component; that is, who had been randomized to either continue or discontinue ART after risk of HIV vertical transmission through breastfeeding was over.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence of AIDS-defining Illness","description":"\"AIDS-defining illness\" refers to the WHO Clinical Stage 4 illnesses listed in Appendix IV. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence of HIV/AIDS-related Events","description":"\"HIV/AIDS-related event\" refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":null},{"groupId":"OG001","value":"1.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence Rate of Cardiovascular or Other Metabolic Events","description":"Cardiovascular or metabolic events of particular concern were included in this analysis. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates.\n\nMetabolic events considered were diabetes mellitus, lipodystrophy, or dyslipidemia. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Other Targeted Medical Conditions","description":"Other (non-cardiologic) medical conditions of particular concern were included in this outcome. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Events included were metabolic events, hepatic events, renal events, infections such as pulmonary tuberculosis, malaria, or other serious bacterial infections, and others.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence of HIV/AIDS-related Event or Death","description":"\"HIV/AIDS-related event\" refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"1.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence of HIV/AIDS-related Event or World Health Organization (WHO) Clinical Stage 2 or 3 Events","description":"\"HIV/AIDS-related event\" refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":null},{"groupId":"OG001","value":"5.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence Rate of Death or Any Condition of Particular Concern","description":"Particular events were targeted as those of particular concern. This outcome considered all such events: death, events defining WHO stages II, III, or IV, targeted cardiovascular adverse events, other targeted adverse events, or cancers which were not AIDS-defining. A complete list can be found in Appendix IV of the Protocol. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence of Tuberculosis","description":"Incidence of tuberculosis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null},{"groupId":"OG001","value":"0.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Toxicity: Incidence of Grade 3 or Greater Laboratory Results or Signs and Symptoms and Selected Grade 2 Hematologic, Renal, and Hepatic Laboratory Results","description":"The maternal safety endpoints summarized include grade 2, 3 or 4 hematologies (hemoglobin (Hb), White Blood Cells (WBC), Absolute Neutrophil Count (ANC), platelet count), chemistries (Alanine Aminotransferase (ALT or SGPT), serum creatinine), and grade 3 or 4 signs and symptoms that occurred post-randomization. These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Health Component: Incidence Rate of Progression to AIDS-defining Illness, Death, or a Serious Non-AIDS Cardiovascular, Hepatic, or Renal Event","description":"This outcome included AIDS-defining illnesses or cardiovascular, hepatic, or renal adverse events of particular concern which were evaluated as serious. Serious outcomes were both those defined as serious according to the International Conference on Harmonization (ICH) definition, or outcomes with grades equal to or worse than 3 (\"Severe\"). A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy. Hepatic events considered were cirrhosis and idiopathic sclerosing cholangitis. Renal events considered were renal insufficiency, acute or chronic.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Maternal Health Component: Cost-effectiveness","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since cost-effectiveness was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Maternal Health Component: Changes in Plasma Concentrations of Inflammatory and Thrombogenic Markers","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since inflammation and thrombogenic markers were not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Maternal Health Component: Quality of Life","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since quality of life was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Maternal Health Component: Self-reported Adherence","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since adherence was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Maternal Health Component: Viral Resistance","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since viral resistance was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Postpartum Component: Functional Maternal Antibody and HIV-envelope Binding Responses in Breast Milk and Plasma, Until Cessation of Breastfeeding or 18 Months Postpartum, Whichever Comes First","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since functional maternal antibody and HIV-envelope binding responses were not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Postpartum Component: Pharmacokinetic Parameters of ARV Drugs Measured in Maternal Plasma, Hair, Breast Milk, and Infant Blood (Plasma or Dried Blood Spot) Samples Collected at Birth; Weeks 1, 6, 14, and 26; and Subsequent Visits During Breastfeeding","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since pharmacokinetics was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Postpartum Component: Cost-effectiveness and Feasibility of the Study ARV Prophylaxis Regimens","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since cost-effectiveness was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Postpartum Component: Rates and Patterns of Maternal and Infant Resistance to the Maternal and Infant ARV Regimens","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since viral resistance was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Postpartum Component: Adherence to the Maternal and/or Infant ARV Regimens, as Measured by Maternal Report and Hair Measures","description":"Adherence is by maternal report; adherence through hair analysis is not included here.\n\nThe protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since adherence was not a focus of the study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1003","spread":null},{"groupId":"OG001","value":"1104","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"956","spread":null},{"groupId":"OG001","value":"1081","spread":null}]},{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"888","spread":null},{"groupId":"OG001","value":"1035","spread":null}]},{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"716","spread":null},{"groupId":"OG001","value":"841","spread":null}]},{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"311","spread":null},{"groupId":"OG001","value":"377","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Antepartum Component: Antepartum Change in HBV DNA Viral Load Between Week 8 and Baseline Levels (Using Log HBV DNA) Among Women With Detectable HBV DNA Viral Loads at Baseline and Other HBV Outcome Measures","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome measure since changes in HBV DNA Viral Load was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Antepartum Component: Cost Effectiveness and Feasibility of the Trial ARV Regimens","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome measure since cost effectiveness was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Antepartum Component: Maternal and Infant Viral Resistance to the Maternal and Infant ARV Strategies","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome measure since viral resistance was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Antepartum Component: Adherence to the Maternal Antiretroviral (ARV) Regimen, as Measured by Maternal Report","description":"The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome measure since adherence was not a focus of the study.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":267,"n":1547},"commonTop":["Haemoglobin decreased","Neutrophil count decreased","Alanine aminotransferase increased","Diarrhoea","Cough"]}}}